Citius Oncology (CTOR) Total Non-Current Liabilities (2024 - 2026)

Citius Oncology's Total Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $64.9 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 17.44% year-over-year to $64.9 million; the TTM figure through Mar 2026 stood at $64.9 million (up 17.44% YoY), while the FY2025 annual figure was $55.5 million, changed N/A from the prior year.
• Total Non-Current Liabilities was $64.9 million for Q1 2026 at Citius Oncology, up from $51.0 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $64.9 million in Q1 2026 to a low of $48.6 million in Q4 2024.
• Historically, Total Non-Current Liabilities has averaged $55.7 million across 3 years, with a median of $55.4 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Total Non-Current Liabilities increased 4.87% in 2025, then grew 17.44% in 2026.
• A 3-year view of Total Non-Current Liabilities shows it stood at $48.6 million in 2024, then grew by 4.87% to $51.0 million in 2025, then increased by 27.2% to $64.9 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $64.9 million (Q1 2026), $51.0 million (Q4 2025), and $55.5 million (Q3 2025), per Business Quant data.